Within3, whose platform is trusted by all of the top 20 pharma companies to turn public data, private data, and expert networks into decision-ready evidence, today announced the appointment of Ira Daly as Chief Operating Officer. Daly joins Within3 after more than 18 years at IQVIA, where he built and led multi-billion-dollar business development teams serving pharma, biotech, and medtech companies across therapeutic areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110080964/en/

Within3 Appoints Ira Daly as Chief Operating Officer

Within3 Appoints Ira Daly as Chief Operating Officer

Most recently, Daly served as Senior Vice President, Offering Development at IQVIA, where he built a matrixed team of data and analytics experts and developed AI agents to improve how solutions reach and support customers. Previously, as Senior Vice President of Biotech and Midsize Business Development for the US and Canada, he led a large team of business development professionals and forged partnerships with biotech companies, academic institutions, venture capital firms, and patient organizations. Over his career, he has supported the approval of numerous new treatments. Daly holds a Master of Science in Cell and Molecular Biology from Fordham University and a Bachelor of Science in Chemistry from Saint Joseph’s University.

“Ira understands that the most valuable partnerships in our industry are built over years, not contracts, and that is exactly what Within3 needs as we enter our next phase of growth,” said Erin Mistry, Chief Executive Officer of Within3. “Our clients increasingly want a trusted partner embedded with their business and technology teams, one that understands the clinical and commercial questions shaping their future, not just their day-to-day. Ira will help us become that partner for every client we serve.”

Aly Madjerich, Senior Vice President, Global Marketing, added, “I’m thrilled to have Ira’s depth of industry experience on the team – and a partner who shares our commitment to relationships built on honest conversations and a willingness to tackle tough problems, together. Those relationships are essential to building solutions that better serve the industry and the patients who depend on it.”

“Throughout my career, I’ve seen how the right partner can influence the success of a development program, if and how physicians prescribe the treatment, and ultimately its commercial success,” said Daly. “Within3 offers biopharma teams something they’ve never had: a connected, real-time view of the market, so they can act when it matters most. I’m excited to help more clients put that intelligence to work and to build partnerships that deliver measurable results.”

As Chief Operating Officer, Daly will lead Within3’s business development, client success, and strategic partnerships, aligning the company’s commercial and client teams around a single goal: helping biopharmaceutical teams make decisions with confidence across their portfolio and at every lifecycle stage. He will focus on scaling Within3’s partnerships with emerging biotechs and global pharma alike, and on ensuring every client realizes the full value of Within3’s technology and services.

About Within3

Trusted by all of the top 20 pharmaceutical companies, Within3 delivers decision-ready evidence by uncovering the hidden influencers shaping clinical practice and capturing market shifts as they emerge, all in a shared, compliant view.

Media gallery

About The Author
Business Wire